Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Synkir-310
- Development stage
- Phase 1
- Lead developer
- Verismo Therapeutics
- Modality
- Gene Addition/Replacement → Gene Therapies, Gene Silencing → Gene Therapies, Gene Editing → Gene Therapies, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
SynKIR-310 is a chimeric antigen receptor (CAR) T-cell therapy developed using Verismo Therapeutics' proprietary KIR-CAR platform. It targets CD19, a protein commonly expressed on the surface of B-cell malignancies, using the DS191 binder. Unlike traditional CAR T therapies, SynKIR-310 incorporates killer immunoglobulin-like receptor (KIR) and DAP12 split signaling domains to enhance T-cell activation and co-stimulation, which may prolong antitumor T-cell function and persistence. This design aims to address challenges such as early relapse in patients with advanced B cell lymphomas. The drug is currently being evaluated in phase 1 clinical trials for relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL), including subtypes such as diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma, mediastinal large B-cell lymphoma, high-grade B-cell lymphomas with MYC/BCL2/BCL6 rearrangements, indolent/aggressive forms of NHL, Epstein-Barr virus positive lymphomas, and others[1][3][4][5][7][8].
- Brand names
- SynKIR
- Other names
- SynKIR™-310
02
Targets
Beyond the preview
Go deeper on Synkir-310.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Synkir-310.